CLEC9A and neoplasm: In the clinic, the tumor/stroma-targeting bispecific, fibroblast activation protein (FAP)-CD40, increased DC-LAMP+ DCs and reduced CLEC9A+ DCs (cDC1) within solid tumors, with the full results yet to be published.78